Nano Letters · 2023 · 14 citations · 20 references
PharmacyBiotechnologyImmunologyAntibody EngineeringImmunotherapyMonoclonal AntibodiesAntibody ConjugationAntibody Specificity EngineeringBispecific AntibodiesChimeric Antigen Receptor T-cell TherapyImmune Checkpoint InhibitorsTherapeutic Monoclonal AntibodiesAntibodiesCd8 T Cell ActivationCheckpoint Inhibitor AntibodiesCheckpoint Therapeutic AntibodiesChimeric Monoclonal AntibodiesMultispecific Antibody DesignT-cell EpitopesTherapeutic Antibody Design
Multispecific antibodies (MsAbs) maintain the specificity of versatile antibodies while simultaneously addressing different epitopes for a cumulative, collaborative effect. They could be an alternative treatment to chimeric antigen receptor-T cell therapy by helping to redirect T cells to tumors in vivo . However, one major limitation of their development is their relatively complex production process, which involves performance of a massive screen with low yield, inconsistent quality, and nonnegligible impurities. Here, a poly( l -glutamic acid)-conjugated multiple Fc binding peptide-based synthesis nanoplatform was proposed, in which MsAbs were constructed by mixing the desired monoclonal antibodies (mAbs) with polymeric Fc binding peptides in aqueous solution without purification. To determine its efficacy, a dual immune checkpoint-based PD1/OX40 bispecific antibody and PDL1/CD3e/4-1BB trispecific antibody-based T cell engager were generated to trigger antitumor CD8 + T responses in mice, showing superior tumor suppression over free mixed mAbs. In this study, a facile, versatile build platform for MsAbs was established.
20
CD8+ T cells regulate tumour ferroptosis during cancer immunotherapy
Weimin Wang, Michael D. Green, Jae Eun Choi et al. · Nature · 2019 · 2.8K citations · Full text
Life Sciences, Immunology, Oncology +16
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
Hagop Kantarjian, Anthony S. Stein, Nicola Gökbuget et al. · New England Journal of Medicine · 2017 · 2.1K citations · Full text
Medicine, Hematology, Oncology +16
MYC regulates the antitumor immune response through CD47 and PD-L1
Stephanie C. Casey, Ling Tong, Yulin Li et al. · Science · 2016 · 1.4K citations · Full text
Medicine, Cancer Biology, Oncology +17
T-helper-1-cell cytokines drive cancer into senescence
Heidi Braumüller, Thomas Wieder, Ellen Brenner et al. · Nature · 2013 · 715 citations
Medicine, Immunology, Oncology +12